BACKGROUND: Few studies have examined the changes in lipoproteins over time and how inflammation is associated with lipoprotein concentrations among patients with end-stage renal disease on dialysis. One possible explanation for the association of low LDL cholesterol concentration and adverse outcomes is that inflammation reduces selected apolipoprotein concentrations. METHODS: Serum samples were collected from a subsample of patients enrolled into the Comprehensive Dialysis Study every 3 months for up to 1 year. We examined the relation between temporal patterns in levels of inflammatory markers and changes in apolipoproteins (apo) A1 and B and the apo B/A1 ratio using linear mixed effects modeling and adjusting for potential confounders. RESULTS: We enrolled 266 participants from 56 dialysis facilities. The mean age was 62 years, 45% were women and 26% were black. Apo A1 was lower among patients with higher Quetelet's (body mass) index (BMI), diabetes mellitus and atherosclerosis. Apo B was lower among older patients, patients with higher serum creatinine and patients with lower BMI. Over the course of a year, apo A1 changed inversely with serum concentrations of the acute phase proteins C-reactive protein (CRP) and α1 acid glycoprotein (α1AG), while apo B did not. Changes in α1AG were more strongly associated with changes in apolipoprotein concentrations than were changes in CRP; increases in α1AG were associated with decreases in apo A1 and increases in the apo B/A1 ratio. CONCLUSIONS: Changes in inflammatory markers were associated with changes in apo A1, but not apo B over 1 year, suggesting that reductions in high-density lipoprotein cholesterol are associated with inflammation, either of which could mediate cardiovascular risk, but not supporting a hypothesis linking increased risk of low levels of apo B containing lipoproteins to the risk associated with inflammation.
BACKGROUND: Few studies have examined the changes in lipoproteins over time and how inflammation is associated with lipoprotein concentrations among patients with end-stage renal disease on dialysis. One possible explanation for the association of low LDL cholesterol concentration and adverse outcomes is that inflammation reduces selected apolipoprotein concentrations. METHODS: Serum samples were collected from a subsample of patients enrolled into the Comprehensive Dialysis Study every 3 months for up to 1 year. We examined the relation between temporal patterns in levels of inflammatory markers and changes in apolipoproteins (apo) A1 and B and the apo B/A1 ratio using linear mixed effects modeling and adjusting for potential confounders. RESULTS: We enrolled 266 participants from 56 dialysis facilities. The mean age was 62 years, 45% were women and 26% were black. Apo A1 was lower among patients with higher Quetelet's (body mass) index (BMI), diabetes mellitus and atherosclerosis. Apo B was lower among older patients, patients with higher serum creatinine and patients with lower BMI. Over the course of a year, apo A1 changed inversely with serum concentrations of the acute phase proteins C-reactive protein (CRP) and α1 acid glycoprotein (α1AG), while apo B did not. Changes in α1AG were more strongly associated with changes in apolipoprotein concentrations than were changes in CRP; increases in α1AG were associated with decreases in apo A1 and increases in the apo B/A1 ratio. CONCLUSIONS: Changes in inflammatory markers were associated with changes in apo A1, but not apo B over 1 year, suggesting that reductions in high-density lipoprotein cholesterol are associated with inflammation, either of which could mediate cardiovascular risk, but not supporting a hypothesis linking increased risk of low levels of apo B containing lipoproteins to the risk associated with inflammation.
Authors: Ryan D Kilpatrick; Charles J McAllister; Csaba P Kovesdy; Stephen F Derose; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: J Am Soc Nephrol Date: 2006-12-13 Impact factor: 10.121
Authors: Nancy G Kutner; Kirsten L Johansen; George A Kaysen; Sarah Pederson; Shu-Cheng Chen; Lawrence Y Agodoa; Paul W Eggers; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2009-03-04 Impact factor: 8.237
Authors: Ian H de Boer; Brad C Astor; Holly Kramer; Walter Palmas; Stephen L Seliger; Michael G Shlipak; David S Siscovick; Michael Y Tsai; Bryan Kestenbaum Journal: Clin J Am Soc Nephrol Date: 2007-12-05 Impact factor: 8.237
Authors: Anisa Jahangiri; Maria C de Beer; Victoria Noffsinger; Lisa R Tannock; Chandrashekar Ramaiah; Nancy R Webb; Deneys R van der Westhuyzen; Frederick C de Beer Journal: Arterioscler Thromb Vasc Biol Date: 2008-11-13 Impact factor: 8.311
Authors: Qianyi Ma; Ayse B Ozel; Shweta Ramdas; Beth McGee; Rami Khoriaty; David Siemieniak; Hong-Dong Li; Yuanfang Guan; Lawrence C Brody; James L Mills; Anne M Molloy; David Ginsburg; Jun Z Li; Karl C Desch Journal: Blood Date: 2014-09-10 Impact factor: 22.113
Authors: George A Kaysen; Barbara Grimes; Lorien S Dalrymple; Glenn M Chertow; Julie H Ishida; Cynthia Delgado; Mark Segal; Janet Chiang; Tjien Dwyer; Kirsten L Johansen Journal: J Clin Lipidol Date: 2017-12-27 Impact factor: 4.766
Authors: George A Kaysen; Xiaoling Ye; Jochen G Raimann; Yuedong Wang; Alice Topping; Len A Usvyat; Stefano Stuard; Bernard Canaud; Frank M van der Sande; Jeroen P Kooman; Peter Kotanko Journal: J Lipid Res Date: 2018-06-12 Impact factor: 5.922